Search

Your search keyword '"Soriano, Enrique R."' showing total 603 results
Start Over Author "Soriano, Enrique R." Publication Year Range Last 50 years
603 results on '"Soriano, Enrique R."'

3. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

Author

Machado, Pedro M, Schäfer, Martin, Mahil, Satveer K, Liew, Jean, Gossec, Laure, Dand, Nick, Pfeil, Alexander, Strangfeld, Anja, Regierer, Anne Constanze, Fautrel, Bruno, Alonso, Carla Gimena, Saad, Carla GS, Griffiths, Christopher EM, Lomater, Claudia, Miceli-Richard, Corinne, Wendling, Daniel, Rodriguez, Deshire Alpizar, Wiek, Dieter, Mateus, Elsa F, Sirotich, Emily, Soriano, Enrique R, Ribeiro, Francinne Machado, Omura, Felipe, Martins, Frederico Rajão, Santos, Helena, Dau, Jonathan, Barker, Jonathan N, Hausmann, Jonathan, Hyrich, Kimme L, Gensler, Lianne, Silva, Ligia, Jacobsohn, Lindsay, Carmona, Loreto, Pinheiro, Marcelo M, Zelaya, Marcos David, de los Ángeles Severina, María, Yates, Mark, Dubreuil, Maureen, Gore-Massy, Monique, Romeo, Nicoletta, Haroon, Nigil, Sufka, Paul, Grainger, Rebecca, Hasseli, Rebecca, Lawson-Tovey, Saskia, Bhana, Suleman, Pham, Thao, Olofsson, Tor, Bautista-Molano, Wilson, Wallace, Zachary S, Yiu, Zenas ZN, Yazdany, Jinoos, Robinson, Philip C, and Smith, Catherine H

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Aging, Clinical Research, Arthritis, Autoimmune Disease, Psoriasis, Good Health and Well Being, Adult, Humans, Male, Arthritis, Psoriatic, Rheumatology, COVID-19, Axial Spondyloarthritis, Physicians, Glucocorticoids, Interleukin-12, Registries, Covid-19, Psoriatic, Autoimmunity, Spondylitis, Ankylosing, Spondylitis, Ankylosing, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectivesTo investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).MethodsDemographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale was defined: no hospitalisation, hospitalisation (and no death) and death. ORs were estimated using multivariable ordinal logistic regression.ResultsOf 5045 cases, 18.3% had PsO, 45.5% PsA and 36.3% axSpA. Most (83.6%) were not hospitalised, 14.6% were hospitalised and 1.8% died. Older age was non-linearly associated with COVID-19 severity. Male sex (OR 1.54, 95% CI 1.30 to 1.83), cardiovascular, respiratory, renal, metabolic and cancer comorbidities (ORs 1.25-2.89), moderate/high disease activity and/or glucocorticoid use (ORs 1.39-2.23, vs remission/low disease activity and no glucocorticoids) were associated with increased odds of severe COVID-19. Later pandemic time periods (ORs 0.42-0.52, vs until 15 June 2020), PsO (OR 0.49, 95% CI 0.37 to 0.65, vs PsA) and baseline exposure to TNFi, IL17i and IL-23i/IL-12+23i (OR 0.57, 95% CI 0.44 to 0.73; OR 0.62, 95% CI 0.45 to 0.87; OR 0.67, 95% CI 0.45 to 0.98; respectively; vs no disease-modifying antirheumatic drug) were associated with reduced odds of severe COVID-19.ConclusionOlder age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with PsO, PsA and axSpA during COVID-19 waves or similar future respiratory pandemics.

Published
2023

4. Does the Use of Immunosuppressive Drugs Impact on SARS-CoV-2 Infection Outcome? Data From A National Cohort of Patients With Immune-Mediated Inflammatory Diseases (SAR-COVID Registry)

Author

Isnardi, Carolina Ayelen, Soriano, Enrique R, Graf, Cesar, de la Vega, María Celina, Pons-Estel, Bernardo A, Roberts, Karen, Quintana, Rosana, Gomez, Gimena, Yazdany, Jinoos, Saurit, Verónica, Báez, Roberto Miguel, Coello, Vanessa Viviana Castro, Pisoni, Cecilia Nora, Berbotto, Guillermo, Vivero, Florencia, Zelaya, Marcos David, Salinas, María J Haye, Torres, Álvaro A Reyes, Ornella, Sofía, Nieto, Romina Estefanía, Maldonado, Federico Nicolás, Gamba, María Julieta, de los Ángeles Severina, María, Tissera, Yohana, Alba, Paula, Cogo, Adriana Karina, Alle, Gelsomina, Gobbi, Carla, Baños, Andrea, Velozo, Edson, Pera, Mariana, Tanten, Romina, Albiero, Juan Alejandro, Ficco, Hernán Maldonado, Martire, María Victoria, Elkin, María Soledad Gálvez, Cosatti, Micaela, Cusa, María Alejandra, Pereira, Dora, Savio, Verónica G, and Pons-Estel, Guillermo J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Arthritis, Clinical Research, Autoimmune Disease, Lung, Infectious Diseases, Inflammatory and immune system, Good Health and Well Being, Adult, Humans, COVID-19, SARS-CoV-2, Immunomodulating Agents, Arthritis, Rheumatoid, Immunosuppressive Agents, Registries, rheumatic diseases, Argentina, Arthritis & Rheumatology, Clinical sciences
Abstract

Background/objectiveThis study describes the impact of immunomodulatory and/or immunosuppressive (IM/IS) drugs in the outcomes of COVID-19 infection in a cohort of patients with immune-mediated inflammatory diseases (IMIDs).MethodsAdult patients with IMIDs with a confirmed SARS-CoV-2 infection were included. Data were reported by the treating physician between August 13, 2020 and July 31, 2021. Sociodemographic data, comorbidities, and DMARDs, as well as clinical characteristics, complications, and treatment of the SARS-CoV-2 infection, were recorded. Descriptive analysis and multivariable logistic regression models were carried out.ResultsA total of 1672 patients with IMIDs were included, of whom 1402 were treated with IM/IS drugs. The most frequent diseases were rheumatoid arthritis (47.7%) and systemic lupus erythematosus (18.4%). COVID-19 symptoms were present in 95.2% of the patients. A total of 461 (27.6%) patients were hospitalized, 8.2% were admitted to the intensive care unit, and 4.4% died due to COVID-19.Patients without IM/IS treatment used glucocorticoids less frequently but at higher doses, had higher levels of disease activity, were significantly older, were more frequently hospitalized, admitted to the intensive care unit, and died due to COVID-19. After adjusting for these factors, treatment with IM/IS drugs was not associated with a worse COVID-19 outcome (World Health Organization-Ordinal Scale ≥5) (odds ratio, 1.24; 95% confidence interval, 0.73-2.06).ConclusionsSAR-COVID is the first multicenter Argentine registry collecting data from patients with rheumatic diseases and SARS-CoV-2 infection. After adjusting for relevant covariates, treatment with IM/IS drugs was not associated with severe COVID-19 in patients with IMIDs.Study registrationThis study has been registered in ClinicalTrials.gov under the number NCT04568421.

Published
2023

6. Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis

Author

Bautista-Molano, Wilson, Fernández-Ávila, Daniel G., Brance, María Lorena, Ávila Pedretti, María Gabriela, Burgos-Vargas, Ruben, Corbacho, Inés, Cosentino, Vanesa Laura, Díaz Coto, José Francisco, Giraldo Ho, Enrique, Gomes Resende, Gustavo, Gutiérrez, Luis Arturo, Gutiérrez, Marwin, Ibáñez Vodnizza, Sebastián Eduardo, Jáuregui, Edwin, Ocampo, Vanessa, Palleiro Rivero, Daniel Ruben, Palominos, Penélope Esther, Pacheco Tena, Cesar, Quiceno, Guillermo Andrés, Saldarriaga-Rivera, Lina María, Sommerfleck, Fernando Andrés, Goecke Sariego, Annelise, Vera Barrezueta, Claudia, Vega Espinoza, Luis Enrique, Vega Hinojosa, Oscar, Citera, Gustavo, Lozada, Carlos, Sampaio-Barros, Percival D., Schneeberger, Emilce, and Soriano, Enrique R.

Published
2023
Full Text
View/download PDF

8. Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry

Author

Isnardi, Carolina A., Roberts, Karen, Saurit, Verónica, Petkovic, Ingrid, Báez, Roberto M., Quintana, Rosana, Tissera, Yohana, Ornella, Sofía, D.Angelo Exeni, Maria Eugenia, Pisoni, Cecilia N., Castro Coello, Vanessa V., Berbotto, Guillermo, Haye Salinas, María J., Velozo, Edson, Reyes Torres, Álvaro A., Tanten, Romina, Zelaya, Marcos D., Gobbi, Carla, Alonso, Carla G., de los Ángeles Severina, María, Vivero, Florencia, Paula, Alba, Cogo, Adriana K., Alle, Gelsomina, Pera, Mariana, Nieto, Romina E., Cosatti, Micaela, Asnal, Cecilia, Pereira, Dora, Albiero, Juan A., Savio, Verónica G., Maldonado, Federico N., Gamba, María Julieta, Germán, Noelia F., Baños, Andrea, Gallino Yanzi, Josefina, Gálvez Elkin, María Soledad, Morbiducci, Julieta S., Martire, María Victoria, Maldonado Ficco, Hernán, Schmid, Maria Marcela, Villafañe Torres, Jaime A., de los Ángeles Correa, Maria, Medina, María Alejandra, Cusa, María Alejandra, Scafati, Julia, Agüero, Santiago E., Lloves Schenone, Nicolás M., Soriano, Enrique R., Graf, Cesar, Pons-Estel, Bernardo A., Gomez, Gimena, Landi, Margarita, De la Vega, María Celina, and Pons-Estel, Guillermo J.

Published
2023
Full Text
View/download PDF

10. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

Author

Coates, Laura C., Soriano, Enrique R., Corp, Nadia, Bertheussen, Heidi, Callis Duffin, Kristina, Campanholo, Cristiano B., Chau, Jeffrey, Eder, Lihi, Fernández-Ávila, Daniel G., FitzGerald, Oliver, Garg, Amit, Gladman, Dafna D., Goel, Niti, Helliwell, Philip S., Husni, M. Elaine, Jadon, Deepak R., Katz, Arnon, Laheru, Dhruvkumar, Latella, John, Leung, Ying-Ying, Lindsay, Christine, Lubrano, Ennio, Mazzuoccolo, Luis Daniel, Mease, Philip J., O’Sullivan, Denis, Ogdie, Alexis, Olsder, Wendy, Palominos, Penelope Esther, Schick, Lori, Steinkoenig, Ingrid, de Wit, Maarten, van der Windt, D. A., and Kavanaugh, Arthur

Published
2022
Full Text
View/download PDF

13. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial

Author

Gladman, Dafna D., Mease, Philip J., Bird, Paul, Soriano, Enrique R., Chakravarty, Soumya D., Shawi, May, Xu, Stephen, Quinn, Sean T., Gong, Cinty, Leibowitz, Evan, Poddubnyy, Denis, Tam, Lai-Shan, Helliwell, Philip S., Kavanaugh, Arthur, Deodhar, Atul, Østergaard, Mikkel, and Baraliakos, Xenofon

Published
2022
Full Text
View/download PDF

15. Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals.

Author

Ribeiro, Andre L, Singla, Shikha, Chandran, Vinod, Chronis, Nicholas, Liao, Wilson, Lindsay, Christine, Soriano, Enrique R, Mease, Philip J, and Proft, Fabian

Subjects
MEDICAL personnel, TREATMENT failure, PHYSICIANS, DEMOGRAPHIC surveys, DERMATOLOGISTS
Abstract

Objectives This study contributes to the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)'s effort to define 'difficult-to-treat' PsA (D2T-PsA), leveraging insights of healthcare professionals who are GRAPPA members. The primary objective is to inform GRAPPA's D2T PsA project, ensuring the consensus definition reflects clinical experience and expertise. Methods An online survey was conducted among GRAPPA's healthcare professionals managing PsA patients. The survey covered demographic details, structured questions, and open-ended queries to gather comprehensive insights into the experts' viewpoints. Results About 223 physicians completed the survey, comprising 179 (80.2%) rheumatologists and 40 (17.9%) dermatologists. The majority, 184 (82.5%), favoured establishing distinct definitions for D2T-PsA and complex-to-manage PsA (C2M-PsA). Furthermore, 202 (90.5%) supported a definition that includes objective inflammation signs (clinical, laboratory, imaging, among others). However, opinions varied on the criteria for prior treatment failures, with most (93, 41.7%) favouring a definition that includes at least one conventional synthetic disease-modifying anti-rheumatic drug and two or more biological- or targeted-synthetic-DMARDs with different mechanisms of action. Conclusion The survey reveals a majority opinion among GRAPPA experts favouring the differentiation between D2T-PsA and C2M-PsA, and the inclusion of objective inflammatory markers in these definitions. However, there is less than 50% agreement on the specific treatment failure criteria, particularly regarding the number of therapies needed to classify PsA as D2T. These findings suggest a need for continued discussion to reach a more unified approach in defining D2T-PsA, reflecting the complexity of the condition. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Impact of COVID-19 pandemic on patients with rheumatic diseases in Latin America

Author

Fernández-Ávila, Daniel G., Barahona-Correa, Julián, Romero-Alvernia, Diana, Kowalski, Sergio, Sapag, Ana, Cachafeiro-Vilar, Antonio, Meléndez, Belia, Pastelín, Carlos, Palleiro, Daniel, Arrieta, Dina, Reyes, Gil, Pons-Estel, Guillermo J., Then-Báez, Jossiell, Ugarte-Gil, Manuel F., Cardiel, Mario H., Colman, Nelly, Chávez, Nilmo, Burgos, Paula I., Montufar, Rubén, Sandino, Sayonara, Fuentes-Silva, Yurilis J., and Soriano, Enrique R.

Published
2022
Full Text
View/download PDF

19. Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges

Author

Soriano, Enrique R., Mysler, Eduardo, Rios, Carlos, Xavier, Ricardo M., Cardiel, Mario H., and Citera, Gustavo

Abstract

ABSTRACTIntroductionRheumatoid arthritis (RA) poses significant healthcare challenges in Latin America (LA) due to its high prevalence and unique healthcare dynamics. Despite global advancements, LA faces specific hurdles in effectively managing RA.Areas coveredThis review examines RA epidemiology, treatment strategies, and clinical challenges in LA. RA prevalence varies, with higher rates among indigenous populations. While conventional disease-modifying antirheumatic drugs (csDMARDs) are recommended as first-line therapy, access remains inconsistent. Biologics and targeted synthetic DMARDs are available, but biosimilars have limited accessibility, with drug prices varying significantly. Key barriers include supply interruptions, diagnosis delays, and high non-adherence rates driven by socioeconomic factors. A severe shortage of rheumatologists, particularly in rural areas, affects patient care. Cardiovascular events, comorbidities, and endemic infections further complicate RA management.Expert opinionAlthough RA care in LA has improved through better use of csDMARDs and advanced treatments, major challenges persist, such as a shortage of specialists, limited medical education, and fragmented healthcare systems. Expanding training programs, enhancing telemedicine, and ensuring drug supply continuity are essential. Strengthening clinical research, improving access to affordable treatments, and developing comprehensive, region-specific strategies are crucial to closing the gap between LA and more developed regions in RA care..

Published
2024
Full Text
View/download PDF

20. Current status of the rheumatologists’ workforce in Latin America: a PANLAR collaborative study

Author

Fernández-Ávila, Daniel Gerardo, Patino-Hernandez, Daniela, Kowalskii, Sergio, Vargas-Caselles, Alfredo, Sapag, Ana Maria, Cachafeiro-Vilar, Antonio, Meléndez-Muñoz, Lucia, Santiago-Pastelín, Carlos, Graf, Cesar, Rossetto, Chayanne, Palleiro, Daniel, Trincado, Daniela, Fernández-Ávila, Diana, Arrieta, Dina, Reyes, Gil, Then Baez, Jossiel, Ugarte-Gil, Manuel F., Cardiel, Mario, Colman, Nelly, Chávez, Nilmo, Burgos, Paula I, Montúfar, Ruben, Sandino, Sayonara, Fuentes-Silva, Yurilis, and Soriano, Enrique R.

Published
2021
Full Text
View/download PDF

22. Design of an algorithm for the diagnostic approach of patients with joint pain

Author

Fernández-Ávila, Daniel G., Rojas, María Ximena, Mora, Sergio A., Varela Rojas, Paola, Vanegas-García, Lucía, Sapag-Durán, Ana María, Hormaza, Andrés Alberto, Fernández, Andres Ricardo, Cachafeiro-Vilar, Antonio, Meléndez, Belia Lucía, Caballero-Uribe, Carlo V., Toro-Gutiérrez, Carlos Enrique, Palleiro-Rivero, Daniel Rubén, Jaimes-Fernández, Diego Alejandro, Arrieta, Dina Maria, Álvarez, Fausto, Pinto-Patarroyo, Gineth Paola, Quiceno, Guillermo Andrés, Pons-Estel, Guillermo, Gómez Puerta, Jose A., Báez, Jossiell Then, Bello-Gualtero, Juan Manuel, Gutiérrez, Juan Martín, Segura, Juan Sebastian, Ferreyra, Leandro Gabriel, Stange, Lilith, Saldarriaga, Lina Maria, Ugarte-Gil, Manuel Francisco, Cardiel, Mario H., Moreno, Mario Javier, Quintero, Maritza, Porras, Marlon B., Colman, Nelly, Chávez, Nilmo Noel, Ruiz, Oscar Orlando, Méndez-Patarroyo, Paul, Machado-Xavier, Ricardo, Caicedo, Tomás, Ocampo, Vanessa, Bautista-Molano, Wilson Armando, Medina, Yimy F., Fuentes-Silva, Yurilis Josefina, and Soriano, Enrique R.

Published
2021
Full Text
View/download PDF

24. Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

Author

Coates, Laura C., Soriano, Enrique R., Corp, Nadia, Bertheussen, Heidi, Callis Duffin, Kristina, Campanholo, Cristiano B., Chau, Jeffrey, Eder, Lihi, Fernández-Ávila, Daniel G., FitzGerald, Oliver, Garg, Amit, Gladman, Dafna D., Goel, Niti, Helliwell, Philip S., Husni, M. Elaine, Jadon, Deepak R., Katz, Arnon, Laheru, Dhruvkumar, Latella, John, Leung, Ying-Ying, Lindsay, Christine, Lubrano, Ennio, Mazzuoccolo, Luis Daniel, Mease, Philip J., O’Sullivan, Denis, Ogdie, Alexis, Olsder, Wendy, Palominos, Penelope Esther, Schick, Lori, Steinkoenig, Ingrid, de Wit, Maarten, van der Windt, D. A., and Kavanaugh, Arthur

Published
2022
Full Text
View/download PDF

28. Rheumatology Training in Latin America: A Collaborative Study by the Pan American League of Associations for Rheumatology

Author

Fernández-Ávila, Daniel G., Patino-Hernandez, Daniela, Kowalskii, Sergio, Vargas-Caselles, Alfredo, Sapag, Ana Maria, Cachafeiro-Vilar, Antonio, Meléndez, Belia, Santiago-Pastelín, Carlos, Graf, Cesar, Rossetto, Chayanne, Palleiro, Daniel, Trincado, Daniela, Fernández-Ávila, Diana Carolina, Arrieta, Dina, Reyes, Gil, Baez, Jossiel Then, Ugarte-Gil, Manuel F., Cardiel, Mario, Colman, Nelly, Chávez, Nilmo, Burgos, Paula I., Montufar, Ruben, Sandino, Sayonara, Fuentes-Silva, Yurilis, and Soriano, Enrique R.

Published
2022
Full Text
View/download PDF

30. Time to address the challenge of difficult to treat psoriatic arthritis: results from an international survey

Author

Marzo-Ortega, Helena, primary, Harrison, Stephanie Rose, additional, Nagy, György, additional, Machado, Pedro M, additional, McGonagle, Dennis G, additional, Aydin, Sibel Zehra, additional, Almodovar-González, Raquel, additional, Bautista-Molano, Wilson, additional, Gossec, Laure, additional, Lubrano, Ennio, additional, Nash, Peter, additional, Pimentel Santos, Fernando, additional, Soriano, Enrique R, additional, and Siebert, Stefan, additional

Published
2023
Full Text
View/download PDF

31. ‘It’s about time’. Dissemination and evaluation of a global health systems strengthening roadmap for musculoskeletal health – insights and future directions

Author

Briggs, Andrew M, primary, Chua, Jason, additional, Cross, Marita, additional, Ahmad, Nighat Mir, additional, Finucane, Laura, additional, Haq, Syed Atiqul, additional, Joshipura, Manjul, additional, Kalla, Asgar Ali, additional, March, Lyn, additional, Moscogiuri, Federico, additional, Reis, Felipe J J, additional, Sarfraz, Shabnum, additional, Sharma, Saurab, additional, Soriano, Enrique R, additional, and Slater, Helen, additional

Published
2023
Full Text
View/download PDF

34. Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort

Author

Gamboa-Cárdenas, Rocio V, Ugarte-Gil, Manuel F., Loreto, Massardo, Sacnun, Mónica P., Saurit, Verónica, Cardiel, Mario H., Soriano, Enrique R., Pisoni, Cecilia, Galarza-Maldonado, Claudio M., Rios, Carlos, Radominski, Sebastião C., Castelar-Pinheiro, Geraldo da R., Bianchi, Washington Alves, Appenzeller, Simone, da Silveira, Inés Guimarães, de Freitas Zerbini, Cristiano A., Caballero-Uribe, Carlo V., Rojas-Villarraga, Adriana, Guibert-Toledano, Marlene, Ballesteros, Francisco, Montufar, Rubén, Vázquez-Mellado, Janitzia, Esquivel-Valerio, Jorge, De La Torre, Ignacio García, Barile-Fabris, Leonor A., Palezuelos, Fedra Irazoque, Andrade-Ortega, Lilia, Monge, Pablo, Teijeiro, Raquel, Achurra-Castillo, Ángel F., Esteva Spinetti, María H., Alarcón, Graciela S., and Pons-Estel, Bernardo A.

Published
2019
Full Text
View/download PDF

37. Proceedings of the GRAPPA 2022 Executive Retreat

Author

Ng, Beverly Cheok Kuan, primary, Jadon, Deepak, additional, Adebajo, Adewale, additional, Ayan, Gizem, additional, Callis Duffin, Kristina, additional, Chandran, Vinod, additional, Coates, Laura C., additional, D'Agostino, Maria Antonietta, additional, de Vlam, Kurt, additional, Deodhar, Atul, additional, Eder, Lihi, additional, Garg, Amit, additional, Gladman, Dafna D., additional, Goel, Niti, additional, Gottlieb, Alice B., additional, Husni, M. Elaine, additional, Katz, Arnon, additional, Kavanaugh, Arthur, additional, Lubrano, Ennio, additional, Mease, Philip J., additional, Merola, Joseph F., additional, Nash, Peter, additional, Ogdie, Alexis, additional, Pennington, Stephen R., additional, Perez-Chada, Lourdes M., additional, Proft, Fabian, additional, Rosen, Cheryl F., additional, Savage, Laura, additional, Goldenstein-Schainberg, Claudia, additional, Siebert, Stefan, additional, Soriano, Enrique R., additional, Steinkoenig, Ingrid, additional, Tillett, William, additional, Armstrong, April W., additional, and FitzGerald, Oliver, additional

Published
2023
Full Text
View/download PDF

38. GRAPPA 2021 Pilot Grant Award Reports

Author

Kasiem, Fazira R., primary, Yamada, Daisuke, additional, Marin, Josefina, additional, Vis, Marijn, additional, Tillett, William, additional, Hwang, Samuel T., additional, Soriano, Enrique R., additional, FitzGerald, Oliver, additional, and Armstrong, April W., additional

Published
2023
Full Text
View/download PDF

42. Management of Peripheral Arthritis in Patients With Psoriatic Arthritis : An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

Author

Leung, Ying-Ying, V. Korotaeva, Tatiana, Candia, Liliana, Pedersen, Susanne Juhl, Molano, Wilson Bautista, Ruderman, Eric M., Bisoendial, Radjesh, Perez-Alamino, Rodolfo, Olsder, Wendy, Moeller, Burkhard, Grazio, Simeon, Gudu, Tania, Mody, Girish M., Pineda, Carlos, Raffayova, Helena, Rohekar, Sherry, Goldenstein-Schainberg, Claudia, Urena, Sergio R. Gutierrez, Vargas, Julio Cesar Casasola, Meghnathi, Bhowmik, Prasad, Roopa, Richette, Pascal, Miranda, Jose Roberto S., Malliotis, Nikolas, Lindqvist, Ulla, Simon, David, Ezeonyeli, Amara, Soriano, Enrique R., FitzGerald, Oliver, Leung, Ying-Ying, V. Korotaeva, Tatiana, Candia, Liliana, Pedersen, Susanne Juhl, Molano, Wilson Bautista, Ruderman, Eric M., Bisoendial, Radjesh, Perez-Alamino, Rodolfo, Olsder, Wendy, Moeller, Burkhard, Grazio, Simeon, Gudu, Tania, Mody, Girish M., Pineda, Carlos, Raffayova, Helena, Rohekar, Sherry, Goldenstein-Schainberg, Claudia, Urena, Sergio R. Gutierrez, Vargas, Julio Cesar Casasola, Meghnathi, Bhowmik, Prasad, Roopa, Richette, Pascal, Miranda, Jose Roberto S., Malliotis, Nikolas, Lindqvist, Ulla, Simon, David, Ezeonyeli, Amara, Soriano, Enrique R., and FitzGerald, Oliver

Abstract

Objective We aimed to compile evidence for the efficacy and safety of therapeutic options for the peripheral arthritis domain of psoriatic arthritis (PsA) for the revised 2021 Group in Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations. Methods A working group consisting of clinicians and patient research partners was convened. We reviewed the evidence from new randomized controlled trials (RCTs) for PsA treatment from February 19, 2013, to August 28, 2020. We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-informed approach to derive evidence for the classes of therapeutic options for 3 patient groups: (1) naïve to treatment, (2) inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), and (3) inadequate response to biologic DMARDs (bDMARDs). Recommendations were derived through consensus meetings. Results The evidence review included 69 RCTs. We derived GRADE evidence for each class of therapeutic options and achieved consensus for the recommendations. For patients naïve to treatment, the working group strongly recommends csDMARDs (methotrexate, sulfasalazine, leflunomide) and phosphodiesterase 4 inhibitors, and emphasizes regular assessment and early escalation to achieve treatment target. bDMARDs (tumor necrosis factor inhibitors [TNFi], interleukin 17 inhibitors [IL-17i], IL-12/23i, IL-23i) and Janus kinase inhibitors (JAKi) are also strongly recommended. For patients with inadequate response to csDMARDs, we strongly recommend TNFi, IL-17i, IL-12/23i, IL-23i, and JAKi. For those who had prior experience with bDMARDs, we strongly recommend a second TNFi, IL-17i, IL-23i, and JAKi. The evidence supporting nonpharmacological interventions was very low. An expert panel conditionally recommends adequate physical activity, smoking cessation, and diet to control weight gain. Conclusion Evidence supporting optimal therapy for the peripheral arthritis d

Published
2023
Full Text
View/download PDF

43. Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewé

Author

Gladman, Dafna D., Mease, Philip J, Bird, Paul, Soriano, Enrique R., Chakravarty, Soumya D., Shawi, May, Lavie, Frederic, Gong, Cinty, Leibowitz, Evan, Poddubnyy, Denis, Tam, Lai-Shan, Helliwell, Philip S, Kavanaugh, Arthur, Deodhar, Atul A, Østergaard, Mikkel, Baraliakos, Xenofon, Gladman, Dafna D., Mease, Philip J, Bird, Paul, Soriano, Enrique R., Chakravarty, Soumya D., Shawi, May, Lavie, Frederic, Gong, Cinty, Leibowitz, Evan, Poddubnyy, Denis, Tam, Lai-Shan, Helliwell, Philip S, Kavanaugh, Arthur, Deodhar, Atul A, Østergaard, Mikkel, and Baraliakos, Xenofon

Published
2023

44. Proceedings of the GRAPPA 2022 Executive Retreat

Author

Ng, Beverly Cheok Kuan, Jadon, Deepak, Adebajo, Adewale, Ayan, Gizem, Duffin, Kristina Calli, Chandran, Vinod, Coates, Laura C, D'Agostino, Maria Antonietta, de Vlam, Kurt, Deodhar, Atul, Eder, Lihi, Garg, Amit, Gladman, Dafna D, Goel, Niti, Gottlieb, Alice B, Husni, M Elaine, Katz, Arnon, Kavanaugh, Arthur, Lubrano, Ennio, Mease, Philip J, Merola, Joseph F, Nash, Peter, Ogdie, Alexi, Pennington, Stephen R, Perez-Chada, Lourdes M, Proft, Fabian, Rosen, Cheryl F, Savage, Laura, Goldenstein-Schainberg, Claudia, Siebert, Stefan, Soriano, Enrique R, Steinkoenig, Ingrid, Tillett, William, Armstrong, April W, Fitzgerald, Oliver, D'Agostino, Maria Antonietta (ORCID:0000-0002-5347-0060), Ng, Beverly Cheok Kuan, Jadon, Deepak, Adebajo, Adewale, Ayan, Gizem, Duffin, Kristina Calli, Chandran, Vinod, Coates, Laura C, D'Agostino, Maria Antonietta, de Vlam, Kurt, Deodhar, Atul, Eder, Lihi, Garg, Amit, Gladman, Dafna D, Goel, Niti, Gottlieb, Alice B, Husni, M Elaine, Katz, Arnon, Kavanaugh, Arthur, Lubrano, Ennio, Mease, Philip J, Merola, Joseph F, Nash, Peter, Ogdie, Alexi, Pennington, Stephen R, Perez-Chada, Lourdes M, Proft, Fabian, Rosen, Cheryl F, Savage, Laura, Goldenstein-Schainberg, Claudia, Siebert, Stefan, Soriano, Enrique R, Steinkoenig, Ingrid, Tillett, William, Armstrong, April W, Fitzgerald, Oliver, and D'Agostino, Maria Antonietta (ORCID:0000-0002-5347-0060)

Abstract

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) leadership congregated for a strategic planning meeting before the 2022 GRAPPA annual meeting in New York, USA. Meeting aims were to review GRAPPA's performance in relation to its 2016 goals and identify successes and areas for further improvement, identify key GRAPPA priorities and activities for the next 5 years, and explore committee structures to best support these aims.

Published
2023

45. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis

Author

Machado, Pedro M, Schäfer, Martin, Mahil, Satveer K, Liew, Jean, Gossec, Laure, Dand, Nick, Pfeil, Alexander, Strangfeld, Anja, Regierer, Anne Constanze, Fautrel, Bruno, Alonso, Carla Gimena, Saad, Carla G S, Griffiths, Christopher E M, Lomater, Claudia, Miceli-Richard, Corinne, Wendling, Daniel, Alpizar Rodriguez, Deshire, Wiek, Dieter, Mateus, Elsa F, Sirotich, Emily, Soriano, Enrique R, Ribeiro, Francinne Machado, Omura, Felipe, Rajão Martins, Frederico, Santos, Helena, Dau, Jonathan, Barker, Jonathan N, Hausmann, Jonathan, Hyrich, Kimme L, Gensler, Lianne, Silva, Ligia, Jacobsohn, Lindsay, Carmona, Loreto, Pinheiro, Marcelo M, Zelaya, Marcos David, Severina, María de Los Ángeles, Yates, Mark, Dubreuil, Maureen, Gore-Massy, Monique, Romeo, Nicoletta, Haroon, Nigil, Sufka, Paul, Grainger, Rebecca, Hasseli, Rebecca, Lawson-Tovey, Saskia, Bhana, Suleman, Pham, Thao, Olofsson, Tor, Bautista-Molano, Wilson, Wallace, Zachary S, Yiu, Zenas Z N, Yazdany, Jinoos, Robinson, Philip C, Smith, Catherine H, Centro de Estudos de Doenças Crónicas (CEDOC), and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Subjects
SDG 3 - Good Health and Well-being
Abstract

Funding The study received support from the American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR). OBJECTIVES: To investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). METHODS: Demographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale was defined: no hospitalisation, hospitalisation (and no death) and death. ORs were estimated using multivariable ordinal logistic regression. RESULTS: Of 5045 cases, 18.3% had PsO, 45.5% PsA and 36.3% axSpA. Most (83.6%) were not hospitalised, 14.6% were hospitalised and 1.8% died. Older age was non-linearly associated with COVID-19 severity. Male sex (OR 1.54, 95% CI 1.30 to 1.83), cardiovascular, respiratory, renal, metabolic and cancer comorbidities (ORs 1.25-2.89), moderate/high disease activity and/or glucocorticoid use (ORs 1.39-2.23, vs remission/low disease activity and no glucocorticoids) were associated with increased odds of severe COVID-19. Later pandemic time periods (ORs 0.42-0.52, vs until 15 June 2020), PsO (OR 0.49, 95% CI 0.37 to 0.65, vs PsA) and baseline exposure to TNFi, IL17i and IL-23i/IL-12+23i (OR 0.57, 95% CI 0.44 to 0.73; OR 0.62, 95% CI 0.45 to 0.87; OR 0.67, 95% CI 0.45 to 0.98; respectively; vs no disease-modifying antirheumatic drug) were associated with reduced odds of severe COVID-19. CONCLUSION: Older age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with PsO, PsA and axSpA during COVID-19 waves or similar future respiratory pandemics. publishersversion published

Published
2023

46. Pan American League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis

Author

Fernández-Ávila, Daniel G., Bautista-Molano, Wilson, Brance, María Lorena, Ávila Pedretti, María Gabriela, Vargas, Rubén Burgos, Díaz Coto, José Francisco, Gutiérrez, Luis Arturo, Gutiérrez, Marwin, Ho, Enrique Giraldo, Ibáñez Vodnizza, Sebastián Eduardo, Jáuregui, Edwin, Ocampo, Vanessa, Palominos, Penélope Esther, Palleiro Rivero, Daniel Ruben, Quiceno, Guillermo Andrés, Sommerfleck, Fernando Andrés, Vega Espinoza, Luis Enrique, Hinojosa, Oscar Vega, Barrezueta, Claudia Vera, Corbacho, Inés, Cosentino, Vanesa Laura, Sariego, Annelise Goecke, Resende, Gustavo Gomes, Saldarriaga-Rivera, Lina María, Pacheco Tena, Cesar Francisco, Citera, Gustavo, Lozada, Carlos, Ranza, Roberto, Sampaio-Barros, Percival D., Schneeberger, Emilce, and Soriano, Enrique R.

Abstract

ObjectivePsoriatic arthritis (PsA) is chronic disease that compromises multiple domains and might be associated with progressive joint damage, increased mortality, functional limitation, and considerably impaired quality of life. Our objective was to generate evidence-based recommendations on the management of PsA in Pan American League of Associations for Rheumatology (PANLAR) countries.MethodsWe used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT approach to adapt the 2019 recommendations of the European Alliance of Associations for Rheumatology. A working group consisting of rheumatologists from various countries in Latin America identified relevant topics for the treatment of PsA in the region. The methodology team updated the evidence and synthesized the information used to generate the final recommendations. These were then discussed and defined by a panel of 31 rheumatologists from 15 countries.ResultsTheses guidelines report 15 recommendations addressing therapeutic targets, use of antiinflammatory agents and corticosteroids, treatment with disease-modifying antirheumatic drugs (conventional synthetic, biologic, and targeted synthetic), therapeutic failure, optimization of biologic therapy, nonpharmacological interventions, assessment tools, and follow-up of patients with PsA.ConclusionHere we present a set of recommendations to guide decision making in the treatment of PsA in Latin America, based on the best evidence available, considering resources, medical expertise, and the patient’s values and preferences. The successful implementation of these recommendations should be based on clinical practice conditions, healthcare settings in each country, and a tailored evaluation of patients.

Published
2024
Full Text
View/download PDF

48. Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER ‐1 Study

Author

Ritchlin, Christopher T., primary, Deodhar, Atul, additional, Boehncke, Wolf‐Henning, additional, Soriano, Enrique R., additional, Kollmeier, Alexa P., additional, Xu, Xie L., additional, Zazzetti, Federico, additional, Shawi, May, additional, Jiang, Yusang, additional, Sheng, Shihong, additional, and Helliwell, Philip S., additional

Published
2023
Full Text
View/download PDF

49. Towards healthy populations: A need to strengthen systems for musculoskeletal health

Author

Briggs, Andrew M, primary, Betteridge, Neil, additional, Dreinhöfer, Karsten E., additional, Haq, Syed Atiqul, additional, Huckel Schneider, Carmen, additional, Kalla, Asgar Ali, additional, Kopansky-Giles, Deborah, additional, March, Lyn, additional, Sharma, Saurab, additional, Soriano, Enrique R., additional, Woolf, Anthony D., additional, Young, James J., additional, and Slater, Helen, additional

Published
2023
Full Text
View/download PDF

50. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies

Author

Schneeberger, Emilce E., primary, Citera, Gustavo, additional, Nash, Peter, additional, Smolen, Josef S., additional, Mease, Philip J., additional, Soriano, Enrique R., additional, Helling, Claudia, additional, Szumski, Annette E., additional, Mundayat, Rajiv, additional, and de León, Darío Ponce, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results